Kura Oncology Inc [KURA] stock is trading at $8.13, down -3.56%. An important factor to consider is whether the stock is rising or falling in short-term value. The KURA shares have gain 3.44% over the last week, with a monthly amount glided 27.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, BTIG Research downgraded its rating to Neutral on February 06, 2025. On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $27 on the stock. Stifel downgraded its rating to a Hold and decreased its price target to $19 on October 14, 2024. Mizuho initiated its recommendation with a Buy and recommended $26 as its price target on December 22, 2023. BofA Securities started tracking with a Buy rating for this stock on August 11, 2023, and assigned it a price target of $31. In a note dated July 27, 2023, Scotiabank initiated an Sector Perform rating and provided a target price of $10.50 on this stock.
Kura Oncology Inc [KURA] stock has fluctuated between $5.41 and $21.40 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $8.13 at the most recent close of the market. An investor can expect a potential return of 72.2% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -2.64%, Pretax Profit Margin comes in at -2.34%, and Net Profit Margin reading is -2.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.52 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.84 points at the first support level, and at 7.56 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.47, and for the 2nd resistance point, it is at 8.81.
Ratios To Look Out For
For context, Kura Oncology Inc’s Current Ratio is 6.16. On the other hand, the Quick Ratio is 6.16, and the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 8.47, the price to book ratio is 2.31.
Transactions by insiders
Recent insider trading involved WILSON TROY EDWARD, President and CEO, that happened on Aug 12 ’25 when 36506.0 shares were purchased. President and CEO, WILSON TROY EDWARD completed a deal on Aug 13 ’25 to buy 13494.0 shares. Meanwhile, Chief Legal Officer Bair Teresa Brophy sold 1559.0 shares on May 19 ’25.
